AbbVie Inc. ABBV SPX

Healthcare · Drug Manufacturers - General · United States

https://www.abbvie.com

Company Profile ↓

$244.78

+31.97% 1Y

Mkt Cap$432.48B

P/E119.40

P/B-60.45

Div. Yield3.04%

52W High$261.07

52W Low$180.56

Book Value$-3.77

EPS (TTM)$2.05

Company Overview

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Why Investors Should Care

Healthy Margins

Operating margin of 32.2% supports profitability.

Dividend Income

Offers a dividend yield of 3.04%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $61.16B (+8.6% YoY); net profit $4.23B.
Trailing 12 Months Year-on-year growth — revenue +12.4%, earnings -46.2%.
5-Year Trend Long-term compounding — revenue CAGR 1.8%, profit CAGR -29.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	1.75%
1 Year:	12.40%

Compounded Profit Growth

5 Years:	-29.06%
1 Year:	-46.20%

Stock Price Performance

1 Year:	+31.97%
6 Months:	+13.05%
3 Months:	+19.54%
1 Month:	+8.90%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 80% of range

$180.56 $261.07

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
Golden Cross6d ago
RSI (14)56.07 · Neutral

Price Performance

1M+8.90%

3M+19.54%

6M+13.05%

1Y+31.97%

Valuation vs Sector

P/E of 119.40 is above the sector median of 25.41 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Attractive dividend yield of 3.04%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 119.4.
Earnings shrank at -29.1% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

119.40

Industry PE

25.41

Forward P/E

15.06

PEG Ratio

0.63

Book Value

$-3.77

Price to Book

-60.45

P/S

6.40

EV/EBITDA

15.57

Dividend Yield

3.04%

Growth (CAGR)

Revenue 5Y

1.75%

Profit 5Y

-29.06%

Revenue (YoY)

12.40%

Earnings (YoY)

-46.20%

Profitability & Returns

ROCE

10.47%

ROE

-129.24%

ROA

10.03%

Profit Margin

5.79%

Op Margin

32.16%

Gross Margin

72.03%

EPS (Latest Qtr)

$0.39

EPS (TTM)

$2.05

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.52

Current Ratio

0.80

Debt

$72.91B

Total Assets

$136.46B

Current Assets

$33.53B

Working Capital

$-14.23B

Ownership

Promoter Holding

Chg in Prom Hold

FII / Inst Holding

Chg in FII Hold

Financial Snapshot

Enterprise Value

$432.48B

Total Revenue (TTM)

$62.82B

EBITDA

$29.92B

Free Cash Flow

$20.81B

Operating Cash Flow

$21.22B

Shares Outstanding

1.77B

Gross Margin

72.03%

Payout Ratio

325.98%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
5	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
6	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
7	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
8	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%
9	GILD Gilead Sciences, Inc. NDXSPX	130.04	17.69	$161.45B	2.61%	21.23%	43.36%	11.38%	9.79%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	6.54B	6.94B	7.00B	-	7.93B	8.28B	8.24B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.34B	15.42B	15.78B	16.62B	15.00B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00B	4.35B	5.30B	4.55B	4.22B
Gross Profit	5.05B	4.93B	5.24B	4.92B	5.42B	5.38B	5.46B	6.01B	6.34B	6.40B	6.28B	6.13B	6.44B	6.56B	6.70B	-	-	-	9.17B	-	-	-	10.57B	-	-	-	10.95B	-	-	-	8.60B	-	-	-	-	9.34B	11.08B	10.47B	12.07B	10.78B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.36B	5.36B	5.89B	6.26B	6.05B
Operating Income	2.39B	2.36B	-	2.41B	2.66B	2.69B	-	2.90B	2.76B	3.16B	-	3.01B	3.40B	2.62B	-	3.60B	752.00M	3.25B	-	4.10B	4.44B	4.31B	-	4.72B	3.29B	4.60B	-	2.77B	4.51B	2.28B	-	2.80B	4.00B	3.83B	-	3.98B	5.72B	4.58B	5.81B	4.73B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.40B	4.34B	3.52B	5.37B	3.69B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	700.00M	740.00M	739.00M	714.00M	717.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.66B	1.55B	714.00M	2.67B	1.04B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	372.00M	613.00M	526.00M	853.00M	342.00M
Net Income	1.61B	1.60B	1.39B	1.71B	1.92B	1.63B	52.00M	2.78B	1.98B	2.75B	-1.83B	2.46B	741.00M	1.88B	2.80B	3.01B	-738.00M	2.31B	36.00M	3.55B	766.00M	3.18B	4.04B	4.49B	924.00M	3.95B	2.47B	239.00M	2.02B	1.78B	822.00M	1.37B	1.37B	1.56B	-	1.29B	938.00M	186.00M	1.82B	695.00M
Diluted EPS	0.98	0.97	0.85	1.06	1.19	1.01	0.03	1.74	1.26	1.81	-1.23	1.65	0.49	1.26	1.88	2.02	-0.46	1.29	0.01	1.99	0.42	1.78	2.26	2.51	0.51	2.21	1.38	0.13	1.14	1.00	0.46	0.77	0.77	0.88	-	0.72	0.52	0.10	1.02	0.39

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	17.44B	18.38B	18.79B	19.96B	22.86B	25.64B	28.22B	32.75B	33.27B	45.80B	56.20B	58.05B	54.32B	56.33B	61.16B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	17.41B	20.41B	16.90B	18.20B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	40.64B	33.90B	39.43B	42.96B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	21.83B	20.37B	27.54B	22.86B
Operating Income	3.62B	5.82B	5.66B	3.41B	7.54B	9.34B	9.54B	6.38B	12.98B	11.36B	17.92B	18.81B	13.54B	11.89B	20.09B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	24.17B	17.17B	14.91B	17.63B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	2.23B	2.22B	2.81B	2.89B
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	13.48B	6.25B	3.72B	6.60B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	1.63B	1.38B	-570.00M	2.36B
Net Income	3.43B	5.28B	4.13B	1.77B	5.14B	5.95B	5.31B	5.69B	7.88B	4.62B	11.54B	11.84B	4.86B	4.28B	4.23B
Diluted EPS	2.18	3.35	2.56	1.10	3.13	3.63	3.30	3.66	5.28	2.72	6.45	6.63	2.72	2.39	2.36

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	27.01B	29.20B	27.51B	53.05B	66.10B	70.79B	59.35B	89.11B	150.56B	-	138.81B	134.71B	135.16B	133.96B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	28.46B	33.00B	25.58B	29.06B
Cash & Equivalents	10.00M	27.00M	5.90B	9.60B	8.35B	8.40B	5.10B	9.30B	7.29B	39.92B	8.45B	-	9.20B	12.81B	5.52B	5.23B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	3.58B	4.10B	4.18B	4.95B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	11.25B	11.15B	10.92B	12.59B
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	121.52B	124.31B	131.80B	137.19B
Current Liabilities	-	-	6.78B	6.88B	11.39B	10.89B	9.78B	16.64B	17.24B	15.59B	28.66B	-	29.54B	37.84B	38.75B	43.29B
Long Term Debt	-	-	-	-	-	-	-	-	-	67.23B	84.95B	-	59.13B	52.19B	60.34B	58.94B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	63.27B	59.38B	67.14B	67.50B
Total Equity	-	-	-350.00M	4.49B	1.74B	3.94B	4.64B	5.10B	-8.45B	-8.17B	13.08B	-	17.25B	10.36B	3.33B	-3.27B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	1.81B	1.82B	1.83B	1.84B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-	9.96B	13.43B	13.32B	17.59B	-	24.94B	22.84B	18.81B	19.03B
Investing Cash Flow	-	-	-	-	-	-	-274.00M	-1.01B	596.00M	-37.56B	-	-623.00M	-2.01B	-20.82B	-6.64B
Financing Cash Flow	-	-	-	-	-	-3.93B	-5.51B	-14.40B	18.71B	-11.50B	-	-24.80B	-17.22B	-5.21B	-12.72B
Capital Expenditure	-356.00M	-333.00M	-491.00M	-612.00M	-532.00M	-479.00M	-529.00M	-638.00M	-552.00M	-798.00M	-	-695.00M	-777.00M	-974.00M	-1.21B
Free Cash Flow	-	-	-	-	-	-	9.43B	12.79B	12.77B	16.79B	-	24.25B	22.06B	17.83B	17.82B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-483.00M	3.61B	-7.22B	-337.00M
Share Buybacks	-	-	320.00M	665.00M	7.59B	6.03B	1.41B	12.01B	629.00M	978.00M	934.00M	1.49B	1.97B	1.71B	980.00M
Dividends Paid	-	-	2.56B	2.66B	3.29B	3.72B	4.11B	5.58B	6.37B	7.72B	9.26B	10.04B	10.54B	11.03B	11.66B

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	70.0%	62.4%	70.0%	70.2%
Operating Margin %	20.8%	31.6%	30.1%	17.1%	33.0%	36.4%	33.8%	19.5%	39.0%	24.8%	31.9%	32.4%	24.9%	21.1%	32.8%
Net Margin %	19.7%	28.7%	22.0%	8.9%	22.5%	23.2%	18.8%	17.4%	23.7%	10.1%	20.5%	20.4%	9.0%	7.6%	6.9%
ROE %	-	-1,507.1%	91.9%	101.8%	130.4%	128.4%	104.2%	-67.3%	-96.5%	35.3%	-	68.6%	46.9%	128.7%	-129.2%
ROCE %	-	28.8%	25.4%	21.2%	17.9%	16.6%	17.6%	15.2%	17.7%	9.3%	-	17.2%	14.0%	12.3%	22.2%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABBV

Yahoo Finance ue, 14 Jul 2026

AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run

AbbVie stock has delivered a strong 151.6% return over the past five years, yet there is a clear split on valuation. A Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount, while earnings based multiples suggest th…

Yahoo Finance ue, 14 Jul 2026

3 Rock-Solid Dividend Stocks to Buy and Hold for Decades

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.

Yahoo Finance ue, 14 Jul 2026

The Race to Commercialize the World’s Most Powerful Psychedelic

An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.…

Yahoo Finance ue, 14 Jul 2026

What Lilly's Peer-Beating Numbers Cost You

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

Yahoo Finance ue, 14 Jul 2026

HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses

The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.

Yahoo Finance ue, 14 Jul 2026

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Wo…

ABBV — Frequently Asked Questions

What is the current share price of AbbVie Inc. (ABBV)?

As of 2026-07-14 21:23 PDT, AbbVie Inc. (ABBV) trades at $244.78 on NYSE. Its 52-week range is $180.56 to $261.07.

What is the market capitalisation of ABBV?

AbbVie Inc. (ABBV) has a market capitalisation of $432.48B on NYSE.

What is the P/E ratio of ABBV?

ABBV trades at a trailing price-to-earnings (P/E) ratio of 119.40. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -60.45.

Does ABBV pay a dividend?

AbbVie Inc. (ABBV) currently offers a dividend yield of 3.04%.

What is the return on equity (ROE) of ABBV?

ABBV has a return on equity (ROE) of -129.24%. Its return on capital employed (ROCE) is 10.47%.

Is ABBV a good stock to buy?

This page provides a data-driven analysis of AbbVie Inc. (ABBV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

AbbVie Inc. ABBV SPX

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Analyst View

Latest News

AbbVie (ABBV) Stock Looks Fully Priced After A 152% Run

3 Rock-Solid Dividend Stocks to Buy and Hold for Decades

The Race to Commercialize the World’s Most Powerful Psychedelic

What Lilly's Peer-Beating Numbers Cost You

HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

ABBV — Frequently Asked Questions

What is the current share price of AbbVie Inc. (ABBV)?

What is the market capitalisation of ABBV?

What is the P/E ratio of ABBV?

Does ABBV pay a dividend?

What is the return on equity (ROE) of ABBV?

Is ABBV a good stock to buy?

Explore More